Background: There are reports of a high prevalence of maternal peripheral and placental malarial parasitaemia (MP) in southeastern Nigeria following the two-dose regimen of sulphadoxine-pyrimethamine (SP) for intermittent preventive treatment (IPT) of malaria in pregnancy.
Objective: To compare the effectiveness of monthly versus two-dose regimens of SP for IPT of malaria in pregnancy in Enugu, south-eastern Nigeria.
Methods: A randomized controlled trial involving antenatal clinic attendees at the University of Nigeria Teaching Hospital (UNTH), Ituku-Ozalla, Enugu, Nigeria. Pregnant women at gestational ages between 13 - 24 weeks were randomized into two groups; intervention group and control group to receive monthly dosing and a two-dose regimen of IPT-SP respectively. Peripheral and placental malaria parasitaemia (MP) and other outcome measures were compared between the two groups.
Results: Prevalence of placental parasitaemia ( 18% vs. 40.6%; RR: 0.44; 95% CI: 0.27 - 0.72; P < 0.001) and maternal peripheral parasitaemia (10.0% vs. 31.7%; RR: 0.32; 95% CI: 0.16 - 0.61; P < 0.001) were significantly lower in the intervention compared to the control group. Similarly, maternal anaemia (39.0% versus 57.4%, p<0.05), neonatal malaria parasitaemia (5.0% versus 16.8%, p < 0.05) and neonatal anaemia (10.0% versus 23.8%, < 0.05) were all significantly lower in the intervention than the control group. However, the incidence of low birth weight (LBW) did not differ between the two groups (P=1.0).
Conclusion: Monthly IPT-SP is more effective in preventing malaria in pregnancy than the standard two-dose regimen. We recommend the universal adoption of this regimen in all obstetric care units.
Download full-text PDF |
Source |
---|
West Afr J Med
August 2024
Department of Haematology and Immunology, University of Nigeria Teaching Hospital Ituku-Ozalla, Enugu, Nigeria.
Background: There are reports of a high prevalence of maternal peripheral and placental malarial parasitaemia (MP) in southeastern Nigeria following the two-dose regimen of sulphadoxine-pyrimethamine (SP) for intermittent preventive treatment (IPT) of malaria in pregnancy.
Objective: To compare the effectiveness of monthly versus two-dose regimens of SP for IPT of malaria in pregnancy in Enugu, south-eastern Nigeria.
Methods: A randomized controlled trial involving antenatal clinic attendees at the University of Nigeria Teaching Hospital (UNTH), Ituku-Ozalla, Enugu, Nigeria.
NPJ Vaccines
December 2024
State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen University, Xiamen, China.
Hepatitis E virus (HEV) infection is a major cause of acute viral hepatitis worldwide. The efficacy and safety of the HEV239 vaccine have been validated, with protection lasting at least 10 years. This study extended the phase 3 trial of HEV239 (NCT01014845), presenting data on the durability of the anti-HEV IgG response elicited by one or two doses in the participants with different baseline serostatus.
View Article and Find Full Text PDFVaccine
December 2024
Moredun Research Institute, Pentlands Science Park, Midlothian, United Kingdom.
Malignant catarrhal fever (MCF), caused by alcelaphine herpesvirus-1 (AIHV-1) transmitted from wildebeest, is a lethal cattle disease with significant impacts on East African pastoralists. Development of a live attenuated MCF vaccine has prompted research into its use in communities at risk. This study reports results from the first utilisation of the MCF vaccine in locally-owned cattle under field conditions.
View Article and Find Full Text PDFBackground: Some of the hospitalized patients after severe COVID-19 pneumonia experience significant fall in peripheral saturation despite optimal treatment. Because of immune dysregulation in COVID-19 there are indications that prolonged corticosteroids could be considered in treating patients for persistent radiological sequelae and respiratory symptoms.
Objectives: to investigate lung function and lung sequelae on high-resolution CT (HRCT) im COVID-19 patients who were treated with glucocorticoid therapy in two dose regimens with a control group of patients who did not receive additional glucocorticoid therapy.
JAMA Oncol
December 2024
Department of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
Importance: Current chemotherapy regimens for patients with ERBB2 (formerly HER2)-positive breast cancer are associated with considerable morbidity. These patients may benefit from more effective and less toxic therapies.
Objective: To evaluate the safety, immunogenicity, and preliminary efficacy of intratumoral (IT) delivery of conventional type 1 dendritic cells (cDC1) in combination with ERBB2-targeted therapies.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!